Sareum Holdings plc




Biotechnology & Medical Research

Market Closed - London S.E. 11:35:01 2024-06-21 am EDT 5-day change 1st Jan Change
38 GBX +15.15% Intraday chart for Sareum Holdings plc 0.00% -36.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sareum Issues Shares to Settle Facility with RiverFort MT
Sareum falls as issues shares to RiverFort Global AN
Northcoders launches bootcamp; Schroder invests AN
Sareum ups retail offer; SThree nabs former ITV exec AN
Sareum to Increase Retail Offer After Oversubscription MT
EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost AN
Sareum Holdings plc Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Sareum Holdings touts new patent allowance for autoimmune therapy AN
Sareum Bags European Patent for Kinase Inhibitor for Autoimmune Disease MT
Sareum shares slump on widened loss and funding talks AN
Sareum Wraps Up Single Ascending Dose, Food Effect Study in Early-stage Trial of Autoimmune Disease Drug MT
Sareum hails safety profile for SDC-1801 after phase 1 trial AN
AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets AN
Sareum Holdings plc Announces Completion of the Single Ascending Dose Part and the Food Effect Study of its Phase 1a Clinical Trial for the Lead Programme SDC-1801 CI
Sareum's Partner Signs Deal with US Biopharma Company for Cancer Growth Blockers MT
London stocks make largely soft start to 2024 AN
AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal AN
Sareum soars as partner agrees SRA737 licence with US biopharma firm AN
EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer AN
Transcript : Sareum Holdings plc - Shareholder/Analyst Call
Sareum Holdings plc Provides Update on Operational Activities and Pipeline Progress CI
Sareum Holdings draws down on equity prepayment facility AN
Sareum Draws Down GBP300,000 from Equity Prepayment Facility MT
Sareum Doses First Subjects in Food Effects Part of Lead Asset Trial MT
EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings AN
Chart Sareum Holdings plc
More charts
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. SAR Stock
  4. News Sareum Holdings plc
  5. Sareum Wraps Up Single Ascending Dose, Food Effect Study in Early-stage Trial of Autoimmune Disease Drug